Yu Qin1,2, Jennifer R Wang3, Ying Wang4, Priyanka Iyer1,2, Gilbert J Cote1, Naifa L Busaidy1, Ramona Dadu1, Mark Zafereo3, Michelle D Williams5, Renata Ferrarotto6, G Brandon Gunn7, Peng Wei8, Keyur Patel9, Marie-Claude Hofmann1, Maria E Cabanillas1. 1. Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2. Department of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas, USA. 3. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 4. Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 5. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 6. Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 7. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 8. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 9. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
Background: Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid cancer that requires a rapid diagnosis and treatment to achieve disease control. Gene mutation profiling of circulating cell-free DNA (cfDNA) in peripheral blood may help to facilitate early diagnosis and treatment selection. The relatively rapid turnaround time compared with conventional tumor mutation testing is a major advantage. The objectives of this study were to examine the concordance of ATC-related mutations detected in cfDNA with those detected in the corresponding tumor tissue, and to determine the prognostic significance of cfDNA mutations in ATC patients. Methods: The ATC patients who were diagnosed and treated at The University of Texas MD Anderson Cancer Center between January 2015 and February 2018 and who had cfDNA testing were included in this study. cfDNA was collected by blood draw and was analyzed by next-generation sequencing (NGS) using the Guardant360-73 gene platform. Results: A total of 87 patients were included in the study. The most frequently mutated genes detected in cfDNA were TP53, BRAF, and PIK3CA. In 28 treatment naive ATC patients, the concordance rate of detected mutations in TP53, BRAFV600E, and PIK3CA between cfDNA and matched tissue NGS was 82.1%, 92.9%, and 92.9%, respectively. Patients with a PIK3CA mutation detected on cfDNA had worse overall survival (OS) (p = 0.03). This association was observed across various treatment modalities, including surgery, cytotoxic chemotherapy, radiation, and BRAF inhibitor (BRAFi) therapy. With regard to treatment, BRAFi therapy significantly improved ATC OS (p = 0.003). Conclusions: cfDNA is a valuable tool to evaluate a tumor's molecular profile in ATC patients. We identified high concordance rates between the gene mutations identified via cfDNA analysis and those identified from the NGS of the corresponding tumor tissue sequencing. Identified mutations in cfDNA can potentially provide timely information to guide treatment selection and evaluate the prognosis in patients with ATC.
Background: Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid cancer that requires a rapid diagnosis and treatment to achieve disease control. Gene mutation profiling of circulating cell-free DNA (cfDNA) in peripheral blood may help to facilitate early diagnosis and treatment selection. The relatively rapid turnaround time compared with conventional tumor mutation testing is a major advantage. The objectives of this study were to examine the concordance of ATC-related mutations detected in cfDNA with those detected in the corresponding tumor tissue, and to determine the prognostic significance of cfDNA mutations in ATC patients. Methods: The ATC patients who were diagnosed and treated at The University of Texas MD Anderson Cancer Center between January 2015 and February 2018 and who had cfDNA testing were included in this study. cfDNA was collected by blood draw and was analyzed by next-generation sequencing (NGS) using the Guardant360-73 gene platform. Results: A total of 87 patients were included in the study. The most frequently mutated genes detected in cfDNA were TP53, BRAF, and PIK3CA. In 28 treatment naive ATC patients, the concordance rate of detected mutations in TP53, BRAFV600E, and PIK3CA between cfDNA and matched tissue NGS was 82.1%, 92.9%, and 92.9%, respectively. Patients with a PIK3CA mutation detected on cfDNA had worse overall survival (OS) (p = 0.03). This association was observed across various treatment modalities, including surgery, cytotoxic chemotherapy, radiation, and BRAF inhibitor (BRAFi) therapy. With regard to treatment, BRAFi therapy significantly improved ATC OS (p = 0.003). Conclusions: cfDNA is a valuable tool to evaluate a tumor's molecular profile in ATC patients. We identified high concordance rates between the gene mutations identified via cfDNA analysis and those identified from the NGS of the corresponding tumor tissue sequencing. Identified mutations in cfDNA can potentially provide timely information to guide treatment selection and evaluate the prognosis in patients with ATC.
Authors: William J Gibson; Daniel T Ruan; Vera A Paulson; Justine A Barletta; Glenn J Hanna; Stefan Kraft; Antonio Calles; Matthew A Nehs; Francis D Moore; Amaro Taylor-Weiner; Jeremiah A Wala; Travis I Zack; Thomas C Lee; Fiona M Fennessy; Erik K Alexander; Tom Thomas; Pasi A Janne; Levi A Garraway; Scott L Carter; Rameen Beroukhim; Jochen H Lorch; Eliezer M Van Allen Journal: Clin Cancer Res Date: 2016-10-17 Impact factor: 12.531
Authors: Nikhil Wagle; Brian C Grabiner; Eliezer M Van Allen; Ali Amin-Mansour; Amaro Taylor-Weiner; Mara Rosenberg; Nathanael Gray; Justine A Barletta; Yanan Guo; Scott J Swanson; Daniel T Ruan; Glenn J Hanna; Robert I Haddad; Gad Getz; David J Kwiatkowski; Scott L Carter; David M Sabatini; Pasi A Jänne; Levi A Garraway; Jochen H Lorch Journal: N Engl J Med Date: 2014-10-09 Impact factor: 91.245
Authors: Rajesh R Singh; Keyur P Patel; Mark J Routbort; Neelima G Reddy; Bedia A Barkoh; Brian Handal; Rashmi Kanagal-Shamanna; Wesley O Greaves; L Jeffrey Medeiros; Kenneth D Aldape; Rajyalakshmi Luthra Journal: J Mol Diagn Date: 2013-06-26 Impact factor: 5.568
Authors: Vivek Subbiah; Robert J Kreitman; Zev A Wainberg; Jae Yong Cho; Jan H M Schellens; Jean Charles Soria; Patrick Y Wen; Christoph Zielinski; Maria E Cabanillas; Gladys Urbanowitz; Bijoyesh Mookerjee; Dazhe Wang; Fatima Rangwala; Bhumsuk Keam Journal: J Clin Oncol Date: 2017-10-26 Impact factor: 44.544
Authors: Richard B Lanman; Stefanie A Mortimer; Oliver A Zill; Dragan Sebisanovic; Rene Lopez; Sibel Blau; Eric A Collisson; Stephen G Divers; Dave S B Hoon; E Scott Kopetz; Jeeyun Lee; Petros G Nikolinakos; Arthur M Baca; Bahram G Kermani; Helmy Eltoukhy; AmirAli Talasaz Journal: PLoS One Date: 2015-10-16 Impact factor: 3.240
Authors: Asaf Zviran; Rafael C Schulman; Minita Shah; Steven T K Hill; Sunil Deochand; Cole C Khamnei; Dillon Maloney; Kristofer Patel; Will Liao; Adam J Widman; Phillip Wong; Margaret K Callahan; Gavin Ha; Sarah Reed; Denisse Rotem; Dennie Frederick; Tatyana Sharova; Benchun Miao; Tommy Kim; Greg Gydush; Justin Rhoades; Kevin Y Huang; Nathaniel D Omans; Patrick O Bolan; Andrew H Lipsky; Chelston Ang; Murtaza Malbari; Catherine F Spinelli; Selena Kazancioglu; Alexi M Runnels; Samantha Fennessey; Christian Stolte; Federico Gaiti; Giorgio G Inghirami; Viktor Adalsteinsson; Brian Houck-Loomis; Jennifer Ishii; Jedd D Wolchok; Genevieve Boland; Nicolas Robine; Nasser K Altorki; Dan A Landau Journal: Nat Med Date: 2020-06-01 Impact factor: 53.440
Authors: Marie-Claude Hofmann; Muthusamy Kunnimalaiyaan; Jennifer R Wang; Naifa L Busaidy; Steven I Sherman; Stephen Y Lai; Mark Zafereo; Maria E Cabanillas Journal: Endocr Relat Cancer Date: 2022-09-14 Impact factor: 5.900
Authors: Steven G Waguespack; Alexander Drilon; Jessica J Lin; Marcia S Brose; Ray McDermott; Mohammed Almubarak; Jessica Bauman; Michela Casanova; Anuradha Krishnamurthy; Shivaani Kummar; Serge Leyvraz; Do-Youn Oh; Keunchil Park; Davendra Sohal; Eric Sherman; Ricarda Norenberg; Josh D Silvertown; Nicoletta Brega; David S Hong; Maria E Cabanillas Journal: Eur J Endocrinol Date: 2022-04-29 Impact factor: 6.558